Effects of microRNA‑210 on the diagnosis and treatment of prostate cancer

Qu,Yuejun; Huang,Wenqiang

doi:10.3892/mmr.2018.9105

Effects of microRNA‑210 on the diagnosis and treatment of prostate cancer

Authors:
- Yuejun Qu
- Wenqiang Huang
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, The Medical Group of Ping Mei Shenma General Hospital, Pingdingshan, Henan 467000, P.R. China, Department of Medical Laboratory Medicine, Qiannan Medical College for Nationalities, Duyun, Guizhou 558000, P.R. China
Published online on: May 31, 2018 https://doi.org/10.3892/mmr.2018.9105
Pages: 1740-1744

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of microRNA-210 (miR-210) in the diagnosis and treatment of prostate cancer. Venous blood was collected from 30 prostate cancer patients, that were treated in the Medical Group of Ping Mei Shenma General Hospital (Pingdingshan, China) from June 2013 to May 2015, and 20 healthy men. The miR‑210 expression levels in patients and healthy men was quantified. Primary prostate cancer cells were placed in three treatment groups: i) NC group, untreated; ii) BL group, empty vector; and iii) anti‑miR‑210 group, miR‑210 inhibitor‑transfected. Cell proliferation and apoptotic rate were detected by MTT and flow cytometry, respectively. The expression levels of miR‑210 and regulator of differentiation 1 (ROD1) were detected by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and the ROD1 protein expression in each group was detected by western blotting. Cell proliferation rate of the anti‑miR‑210 group was significantly reduced when compared with the NC and BL groups (P≤0.05); however, the apoptotic rate of the anti‑miR‑210 group was significantly increased compared with the NC and BL groups (P≤0.05). RT‑qPCR revealed that the expression level of miR‑210 and ROD1 in the anti‑miR‑210 group was significantly reduced when compared with the NC and BL groups (P<0.05). MiR‑210 was overexpressed in the serum of prostate cancer patients and transfection with an miR‑210 inhibitor was able to effectively inhibit the proliferation of prostate cancer cells and promote apoptosis.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Santanam U, Banach-Petrosky W, Abate-Shen C, Shen MM, White E and DiPaola RS: Atg7 cooperates with Pten loss to drive prostate cancer tumor growth. Genes Dev. 30:399–407. 2016. View Article : Google Scholar : PubMed/NCBI
3	Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J, Rizvanov A, Heery DM, Mongan NP, Maitland NJ, et al: Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow. Cancer Res. 76:2453–2464. 2016. View Article : Google Scholar : PubMed/NCBI
4	Negrini M and Calin GA: Breast cancer metastasis: A microRNA story. Breast Cancer Res. 10:2032008. View Article : Google Scholar : PubMed/NCBI
5	Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, Radova L, Svoboda M, Dolezel J, Vyzula R and Slaby O: MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol. 34:481–491. 2013. View Article : Google Scholar : PubMed/NCBI
6	Bakirzi K, Law IK, Xue X, Iliopoulos D, Shah YM and Pothoulakis C: Neurotensin promotes the development of colitis and intestiinal angiogenesis via Hif-1α-miR-210 signaling. J Immunol. 196:4311–4321. 2016. View Article : Google Scholar : PubMed/NCBI
7	Rane JK, Scaravilli M, Ylipää A, Pellacani D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T and Maitland NJ: MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Eur Urol. 67:7–10. 2015. View Article : Google Scholar : PubMed/NCBI
8	Alhasan AH, Scott AW, Wu JJ, Feng G, Meeks JJ, Thaxton CS and Mirkin CA: Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. Proc Natl Acad Sci USA. 113:10655–10660. 2016. View Article : Google Scholar : PubMed/NCBI
9	Li X, Wan X, Chen H, Yang S, Liu Y, Mo W, Meng D, Du W, Huang Y, Wu H, et al: Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer. Clin Cancer Res. 20:2312–2325. 2014. View Article : Google Scholar : PubMed/NCBI
10	Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, Takahashi S, Fujii Y and Yamashita H: High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol. 42:256–263. 2012. View Article : Google Scholar : PubMed/NCBI
11	Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, Al-Shibli K, Donnem T, Busund LT and Bremnes RM: Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer. 83:272–278. 2014. View Article : Google Scholar : PubMed/NCBI
12	Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB and Gleadle JM: The VHL-dependent regulation of microRNAs in renal cancer. BMC Med. 8:642010. View Article : Google Scholar : PubMed/NCBI
13	Lai NS, Dong QS, Ding H, Miao ZL and Lin YC: MicroRNA-210 overexpression predicts poorer prognosis in glioma patients. J Clin Neurosci. 21:755–760. 2014. View Article : Google Scholar : PubMed/NCBI
14	Cai H, Lin L, Cai H, Tang M and Wang Z: Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol. 30:4992013.Andersen S, Richardsen E, Moi L, Donnem T, Nordby Y, Ness N, Holman ME, Bremnes RM and Busund LT: Fibroblast miR-210 overexpression is independently associated with clinical failure in prostate cancer-a multicenter (in situ hybridization) study. Sci Rep 6: 36573, 2016. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Bray F and Soerjomataram I: The changing global burden of cancer: Transitions in human development and implications for cancer prevention and controlCancer: Disease Control Priorities. Gelband H, Jha P, Sankaranarayanan R and Horton S: 3. 3rd edition. The International Bank for Reconstruction and Development/The World Bank; Washington, DC: 2015
17	Zhang K, Bangma CH and Roobol MJ: Prostate cancer screening in Europe and Asia. Asian J Urol. 4:86–95. 2017. View Article : Google Scholar : PubMed/NCBI
18	Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC and Bizama C: Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget. 6:24750–24779. 2015. View Article : Google Scholar : PubMed/NCBI
19	Taylor DD and Gecel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
20	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
21	Dumont N and Tlsty TD: Reflections on miR-ing effects in metastais. Cancer Cell. 16:3–4. 2009. View Article : Google Scholar : PubMed/NCBI
22	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
23	Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G and Chartrand P: An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 282:2135–2143. 2007. View Article : Google Scholar : PubMed/NCBI
24	McCormick R, Buffa FM, Ragoussis J and Harris AL: The role of hypoxia regulated microRNAs in cancer. Curr Top Microbiol Immunol. 345:47–70. 2010.PubMed/NCBI
25	Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K and Tsujimoto G: MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 286:420–428. 2011. View Article : Google Scholar : PubMed/NCBI
26	White NM, Bao TT, Grigull J, Youssef YM, Girgis A, Diamandis M, Fatoohi E, Metias M, Honey RJ, Stewart R, et al: miRNA profiling for clear cell renal cell carcinoma: Biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol. 186:1077–1083. 2011. View Article : Google Scholar : PubMed/NCBI
27	Zhao A, Li G, Péoc'h M, Genin C and Gigante M: Serum miR-210 as a biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 94:115–120. 2013. View Article : Google Scholar : PubMed/NCBI
28	Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, Guarnera MA, Li R, Cai L, Zhan M and Jiang F: Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 11:3742011. View Article : Google Scholar : PubMed/NCBI
29	Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT and Koong AC: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 3:109–113. 2010. View Article : Google Scholar : PubMed/NCBI
30	Zhang S, Lai N, Liao K, Sun J and Lin Y: MicroRNA-210 regulates cell proliferation and apoptosis by targeting regulator of differentiation 1 in glioblastoma cells. Folia Neuropathol. 53:236–244. 2015. View Article : Google Scholar : PubMed/NCBI
31	Fasanaro P, Romani S, Voellenkie C, Maimone B, Capogrossi MC and Martelli F: ROD1 is a seedless target gene of hypoxia-induced miR-210. PLoS One. 7:e446512012. View Article : Google Scholar : PubMed/NCBI